Melissa C Rhodes

US Patent:

20080004346, Jan 3, 2008

Filed:

Jul 19, 2005

Appl. No.:

11/572349

Inventors:

Neil Frazer - Cary NC, US
Jonathan Heller - Raleigh NC, US
Rocio Lopez - Durham NC, US
Melissa Rhodes - Raleigh NC, US
Ru Chih Huang - Baltimore MD, US
Richard Dalby - Timonium MD, US
Niharika Khanna - Ellicott City MD, US

Assignee:

ERIMOS PHARMACEUTICALS LLC - Houston TX
JOHNS HOPKINS UNIVERSITY - Baltimore MD
UNIVERSITY OF MARYLAND, BALTIMORE - Baltimore MD

International Classification:

A61K 31/015
A61K 31/195
A61P 43/00

US Classification:

514567000, 514764000

Abstract:

The present invention provides for compositions, kits and methods for treatment of intraepithelial neoplasia, where the compositions include catecholic butanes, which include NDGA derivatives.

US Patent:

20080096967, Apr 24, 2008

Filed:

Jan 27, 2006

Appl. No.:

11/814880

Inventors:

Rocio Lopez - Raleigh NC, US
Jessica Blomberg - Raleigh NC, US
Melissa Rhodes - Raleigh NC, US
Jonathan Heller - San Francisco CA, US

Assignee:

ERIMOS PHARMACEUTICALS LLC - Raleigh NC

International Classification:

A61K 31/015
A61K 47/00
A61K 31/05
A61K 31/195
A61P 9/00
A61P 17/00
A61P 1/00
A61P 25/00

US Classification:

514567000, 514773000, 514781000, 514764000, 514734000, 514568000

Abstract:

The present invention provides for a composition, kit and method for treatment of diseases, where the composition contains at least one catecholic butane, including NDGA compounds and derivatives, together with a pharmaceutically acceptable carrier that may include solubilizing agents or excipients, where the composition is suitable for injection into animals.

US Patent:

20090022803, Jan 22, 2009

Filed:

Jan 27, 2006

Appl. No.:

11/814838

Inventors:

Rocio Alejandra Lopez - Raleigh NC, US
Jessica Andrea LoDuca Blomberg - Raleigh NC, US
Melissa Claire Rhodes - Raleigh NC, US
Jonathan Daniel Heller - San Francisco CA, US
Amanda Beth Goodman - Wake Forest NC, US

Assignee:

ERIMOS PHARMACEUTICALS LLC - Raleigh NC

International Classification:

A61K 9/14
A61K 31/24

US Classification:

424486, 424488, 514536

Abstract:

The present invention provides for compositions, kits and methods for treatment of diseases, where the compositions contain catecholic butanes, including NDGA compounds, such as NDGA derivatives, for example tetra-O-methyl NDGA. The present invention also provides for solubilizing agents and excipients that are suitable for administration of the present compounds into animals via an oral route, whether in a liquid, semi-solid or solid form.

US Patent:

20230000866, Jan 5, 2023

Filed:

Jul 18, 2022

Appl. No.:

17/813173

Inventors:

- Basel, CH
Magdalena Alonso-Galicia - Durham NC, US
Thomas Pack - Durham NC, US
Julie Rurka - Raleigh NC, US
David Carpenter - Durham NC, US
Melissa Rhodes - Raleigh NC, US

International Classification:

A61K 31/506
A61P 9/12
A61K 9/00

Abstract:

There is a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day

US Patent:

20200289510, Sep 17, 2020

Filed:

Mar 13, 2020

Appl. No.:

16/818236

Inventors:

- Basel, CH
David Carpenter - Durham NC, US
Thomas Pack - Durham NC, US
Melissa Rhodes - Raleigh NC, US
Julie Rurka - Raleigh NC, US
Steve Wring - South Boston VA, US

International Classification:

A61K 31/506
A61K 9/00
A61P 9/12

Abstract:

There is a method of treating or preventing pulmonary arterial hypertension (PAH) or associated pulmonary arterial hypertension (APAH) in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing PAH or APAH in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day. There is a method for treating PAH or APAH in a patient with a single daily dose.

US Patent:

20200155552, May 21, 2020

Filed:

Nov 15, 2019

Appl. No.:

16/685165

Inventors:

- Basel, CH
Magdalena ALONSO-GALICIA - Durham NC, US
Thomas PACK - Durham NC, US
Julie RURKA - Raleigh NC, US
David CARPENTER - Durham NC, US
Melissa RHODES - Raleigh NC, US

Assignee:

ALTAVANT SCIENCES GmbH - BASEL

International Classification:

A61K 31/506
A61K 9/00
A61P 9/12

Abstract:

There is a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day

US Patent:

20160324852, Nov 10, 2016

Filed:

May 6, 2016

Appl. No.:

15/149053

Inventors:

- Hamilton, BM
Melissa RHODES - Raleigh NC, US
Stephen Clement PISCITELLI - Hillsborough NC, US
Kunal KISHNANI - Flushing NY, US
Shankar RAMASWAMY - Cincinnati OH, US
Bryan M. LEWIS - North Brunswick NJ, US
Geetha RAMASWAMY - New York NY, US

International Classification:

A61K 31/496
A61K 45/06
A61K 9/48
A61K 9/00
A61K 31/445

Abstract:

The present application relates to new uses of 5-HTreceptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, and to the combination of 5-HTreceptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, with other therapeutic agents for the treatment of a neurodegenerative disease.